The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 901–1,000 of 1,005
Scientific Evidence to Support a Vitamin E and Heart Disease Health Claim: Research Needs
Jialal, I., & Devaraj, S. (2005) · Journal of Nutrition · doi:10.1093/jn/135.2.348 · Cited by 48
Mechanisms of Vitamin E Regulation: Research Over the Past Decade and Focus on the Future
Parks, E. J., & Traber, M. G. (2000) · Antioxidants and Redox Signaling · doi:10.1089/15230860050192189 · Cited by 48
Alzheimer disease and other dementias
Alva, G., & Potkin, S. G. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00028-4 · Cited by 48
Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
Cummings, J. L., & Zhong, K. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1928 · Cited by 48
Zandi, P. P. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.82 · Cited by 47
Walia, V., Kaushik, D., Mittal, V., Kumar, K., Verma, R., Parashar, J., Akter, R., Rahman, M. H., Bhatia, S., Al-Harrasi, A., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02617-1 · Cited by 47
Gogna, T., Housden, B. E., & Houldsworth, A. (2024) · Antioxidants · doi:10.3390/antiox13091138 · Cited by 47
Effects of vitamin E on lead-induced impairments in hippocampal synaptic plasticity
Salehi, I., Karamian, R., Komaki, A., Tahmasebi, L., Azandaryani, M. T., Nazari, M., Shahidi, ., & Sarihi, A. (2015) · Brain Research · doi:10.1016/j.brainres.2015.10.007 · Cited by 47
Antioxidants and Alzheimerʼs disease: from bench to bedside (and back again)
Rutten, B. P. F., Steinbusch, H. W. M., Korr, H., & Schmitz, C. (2002) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200211000-00006 · Cited by 47
The potential role of nutritional components in the management of Alzheimer's Disease
van der Beek, E. M., & Kamphuis, P. J. G. H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.049 · Cited by 47
Genetic basis of Alzheimer's dementia: role of mtDNA mutations
Grazina, M. M., Pratas, J., Silva, F., Oliveira, S. A., Santana, I. J., & Oliveira, C. R. (2006) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2006.00225.x · Cited by 47
Lee, I.-M. M., Cook, N. R., & Gaziano, J. M. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.09.029 · Cited by 47
α-Tocopherol protective effects on gentamicin ototoxicity: an experimental study
Fetoni, A. R., Sergi, B., Ferraresi, A., Paludetti, G., & Troiani, D. (2004) · International Journal of Audiology · doi:10.1080/14992020400050023 · Cited by 47
Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
Ma, C., Li, J., Bao, Z., Ruan, Q., & Yu, Z. (2015) · BioMed Research International · doi:10.1155/2015/481621 · Cited by 46
No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia
Rainer, M., Kraxberger, E., Haushofer, M., Mucke, H. A. M., & Jellinger, K. A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070011 · Cited by 46
Karthika, C., Appu, A. P., Akter, R., Rahman, M. H., Tagde, P., Ashraf, G. M., Abdel‐Daim, M. M., Hassan, S. S. U., Abid, A., & BUNGAU, S. G. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17830-7 · Cited by 46
RetractedRevisiting the Role of Vitamins and Minerals in Alzheimer’s Disease
Shah, H., Dehghani, F., Ramezan, M., Gannaban, R. B., Haque, Z. F., Rahimi, F. C., Abbasi, S., & Shin, A. C. (2023) · Antioxidants · doi:10.3390/antiox12020415 · Cited by 48
Spermidine ameliorates the neuronal aging by improving the mitochondrial function in vitro
Jing, Y., Yan, J.-L., Wang, Q., Chen, H., Ma, X.-Z., Yin, J., & Gao, L. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.04.005 · Cited by 46
Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study
Williams, D. M., Hägg, S., & Pedersen, N. L. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy225 · Cited by 46
Therapeutic Options for Cognitive Decline in Senior Pets
Landsberg, G. M. (2006) · Journal of the American Animal Hospital Association · doi:10.5326/0420407 · Cited by 46
Vitamin E Use Is Associated with Improved Survival in an Alzheimer’s Disease Cohort
Pavlik, V., Doody, R. S., Rountree, S. D., & Darby, E. J. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000255105 · Cited by 46
Herbicides - Mechanisms and Mode of Action
Hasaneen, M. N. A. E.-G. (2011) · InTech eBooks · doi:10.5772/2510 · Cited by 46
Post-stroke Dementia: Epidemiology, Mechanisms and Management
Hu, G., & Chen, Y.-M. (2017) · International journal of gerontology · doi:10.1016/j.ijge.2017.07.004 · Cited by 46
Alzheimer's Disease and Its Management in the Year 2010
Cummings, J. L., & Jeste, D. V. (1999) · Psychiatric Services · doi:10.1176/ps.50.9.1173 · Cited by 46
TREATMENT OF ALZHEIMER'S DISEASE
Grundman, M., & Thal, L. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70227-9 · Cited by 46
Self-citationRobinson, R. A. S., Gururaj Joshi, A., Huang, Q., Rukhsana Sultana, A., Baker, A. S., Cai, J., Pierce, W. M. J., Clair, D. K. S., Markesbery, W. R., & Butterfield, D. A. (2011) · PROTEOMICS · doi:10.1002/pmic.201000523 · Cited by 45
Alzheimer’s Pathogenesis and Its Link to the Mitochondrion
Simoncini, C., Orsucci, D., Ienco, E. C., Siciliano, G., Bonuccelli, U., & Mancuso, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/803942 · Cited by 45
Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's β-amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.11.001 · Cited by 45
Koninginins, phospholipase A2 inhibitors from endophytic fungus Trichoderma koningii
de Souza, A. D. L., Filho, E. R., de Souza, A. Q. L., Pereira, J. O., Calgarotto, A. K., Maso, V., Marangoni, S., & Silva, S. L. D. (2007) · Toxicon · doi:10.1016/j.toxicon.2007.09.009 · Cited by 45
Differences in Alzheimer disease clinical trial outcomes based on age of the participants
Schneider, L. S., Kennedy, R., Wang, G., & Cutter, G. (2015) · Neurology · doi:10.1212/wnl.0000000000001376 · Cited by 45
Self-citationEngelhardt, E., Brucki, S. M. D., Cavalcanti, J. L. D. S., Forlenza, O. V., Laks, J., & Vale, F. A. C. (2005) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2005000600035 · Cited by 46
Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease
Wimo, A. B. (2004) · Drugs & Aging · doi:10.2165/00002512-200421050-00001 · Cited by 45
Stress, Aging, and Neurodegenerative Disorders: Molecular Mechanismsa
Busciglio, J. A., Andersen, J. K., Schipper, H. M., Gilad, G. M., McCarty, R. C., Marzatico, F., & Toussaint, O. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09021.x · Cited by 45
Pharmacological interventions for cognitive decline in people with Down syndrome
Livingstone, N., Hanratty, J., McShane, R. H., & Macdonald, G. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011546.pub2 · Cited by 44
Head, E. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1396.004 · Cited by 44
Distinto, S., Meleddu, R., Yáñez, M., Cirilli, R., Bianco, G., Sanna, M. L., Arridu, A., Cossu, P., Cottiglia, F., Faggi, C., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.026 · Cited by 44
Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands
Rodríguez‐Soacha, D. A., Scheiner, M., & Decker, M. W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.040 · Cited by 44
Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
Matthews, D. C., Ritter, A. R., Thomas, R. G., Andrews, R. D., Lukic, A. S., Revta, C., Kinney, J. W., Tousi, B., Leverenz, J. B., Fillit, H. M., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12106 · Cited by 44
Self-citationMitochondrial Oxidant Signalling in Alzheimer's Disease
Viña, J., Lloret, A., Vallés, S. L., Borrás, C., Badía, M.-C., Pallardó, F. V., Sastre, J., & Alonso, M.-D. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11205 · Cited by 44
Therapeutic options in Alzheimer’s disease
Moreira, P. I., Zhu, X., Nunomura, A., Smith, M. A., & Perry, G. L. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.897 · Cited by 44
Micronutrients and Alzheimer's disease
Staehelin, H. B. (2005) · Proceedings of The Nutrition Society · doi:10.1079/pns2005459 · Cited by 44
Study of plasma antioxidant status in Alzheimer's disease
Pulido, R., Jiménez‐Escrig, A., Orensanz, L., Saura-Calixto, F. D., & Jiménez‐Escrig, A. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01000.x · Cited by 44
Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice
Garcı́a-Alloza, M., Borrelli, L. A., Hyman, B. T., & Bacskai, B. J. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.11.006 · Cited by 44
Egger, T., Hammer, A., Wintersperger, A., Goti, D., Malle, E., & Sattler, W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00641.x · Cited by 44
Protective effect of l-Deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells
Suuronen, T., Kolehmainen, P., & Salminen, A. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00282-3 · Cited by 44
The Boyd Orr Lecture: Nutrition interventions in aging and age-associated disease
Meydani, M. (2002) · Proceedings of The Nutrition Society · doi:10.1079/pns2002144 · Cited by 44
Emerging Antidementia Drugs: A Preliminary Ethical View
Post, S. G., & Whitehouse, P. J. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb03819.x · Cited by 44
Mild Cognitive Impairment — No Benefit from Vitamin E, Little from Donepezil
Blacker, D. (2005) · New England Journal of Medicine · doi:10.1056/nejme058086 · Cited by 44
Mitochondrial medicine and the neurodegenerative mitochondriopathies
Swerdlow, R. H. (2009) · Pharmaceuticals · doi:10.3390/ph2030150 · Cited by 43
Kennedy, R., Cutter, G., Wang, G., & Schneider, L. S. S. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.03.001 · Cited by 43
Self-citationSilverman, D. H. S., Cummings, J. L., Small, G. W., Gambhir, S. S., Chen, W., Czernin, J. G., & Phelps, M. E. (2002) · Molecular Imaging and Biology · doi:10.1016/s1536-1632(02)00016-1 · Cited by 43
Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease
Lyketsos, C. G., Reichman, W. E., Kershaw, P. R., & Zhu, Y. (2004) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200409000-00005 · Cited by 43
Systemic and Brain Metabolic Dysfunction as a New Paradigm for Approaching Alzheimer’s Dementia
Giordano, V., Peluso, G., Iannuccelli, M., Benatti, P., Nicolai, R., & Calvani, M. (2006) · Neurochemical Research · doi:10.1007/s11064-006-9125-8 · Cited by 43
Vitamin Supplementation Therapy in the Elderly
Thurman, J. E., & Mooradian, A. D. (1997) · Drugs & Aging · doi:10.2165/00002512-199711060-00003 · Cited by 43
Experimental Basis for Cancer Preventation by Vitamin E
Shklar, G., & Oh, S.-K. (2000) · Cancer Investigation · doi:10.3109/07357900009031826 · Cited by 43
Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale
Marin, D. B., Flynn, S. P., Mare, M., Lantz, M., Hsu, M., Laurans, M., de Paredes, M. D. M.-G., Shreve, T., Zaklad, G. R., & Mohs, R. C. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.385 · Cited by 43
Banerjee, C., Tripathy, D., Kumar, D., & Chakraborty, J. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105831 · Cited by 42
Ashley, S., Bradburn, S., & Murgatroyd, C. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1681066 · Cited by 42
An organo-catalytic approach to the enantioselective synthesis of (R)-selegiline
Talluri, S. K., & Sudalai, A. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.07.012 · Cited by 42
Metal homeostasis in Alzheimer’s disease
White, A. R., Barnham, K. J., & Bush, A. I. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.5.711 · Cited by 42
Siwak, C. T., Tapp, P. D., Head, E., Zicker, S. C., Murphey, H. L., Muggenburg, B. A., Ikeda-Douglas, C. J., Cotman, C. W., & Milgram, N. W. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.12.011 · Cited by 42
Self-citationPrevention of brain aging and dementia
Ball, L. J., & Birge, S. J. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00027-7 · Cited by 42
Pharmacological Interventions in Aging and Age‐associated Disorders
Kitani, K., Minami, C., Yamamoto, T., Kanai, S., Ivy, G. O., & Carrillo, M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02101.x · Cited by 42
Kim, J. W., Byun, M. S., Sohn, B. K., Yi, D., Seo, E. H., Choe, Y. M., Kim, S. G., Choi, H. J., Lee, J. H., Chee, I., et al. (2017) · Psychiatry Investigation · doi:10.4306/pi.2017.14.4.420 · Cited by 42
Reactive Oxygen Species in Diabetes-induced Vascular Damage, Stroke, and Alzheimer's Disease
Muhammad, S., Bierhaus, A., & Schwaninger, M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0982 · Cited by 42
Ali, J., Choe, K., Park, J. S., Park, H. Y., Kang, H., Park, T. J., & Kim, M.-O. (2024) · Antioxidants · doi:10.3390/antiox13070862 · Cited by 42
Panahi, Y., Rajaee, S. M., Johnston, T. P., & Sahebkar, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26536 · Cited by 41
Modulating Effect of Diet on Alzheimer’s Disease
Fernández-Sanz, P., Ruiz-Gabarre, D., & García‐Escudero, V. (2019) · Diseases · doi:10.3390/diseases7010012 · Cited by 41
Vitamin E: necessary nutrient for neural development and cognitive function
Traber, M. G. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121000914 · Cited by 41
Novel therapeutics for Alzheimer's disease: an update.
Bonda, D., Lee, H. P., Lee, H., Friedlich, A. L., Perry, G. L., Zhu, X., & Smith, M. A. (2010) · PubMed · Cited by 41
Nakaso, K., Horikoshi, Y., Takahashi, T., Hanaki, T., Nakasone, M., Kitagawa, Y., Koike, T., & Matsura, T. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.10.062 · Cited by 41
Prevention of Alzheimer's disease
Szekely, C. A., Breitner, J. C. S., & Zandi, P. P. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797944 · Cited by 41
Complementary and alternative therapies for Down syndrome
Roizen, N. (2005) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20063 · Cited by 41
Pharmacotherapeutic approaches to the prevention of Alzheimer's disease
Standridge, J. B. (2004) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/s1543-5946(04)90017-7 · Cited by 41
Plant Foods and Brain Aging: A Critical Appraisal
Schaffer, S., Eckert, G. P., Schmitt-Schillig, S., & Müller, W. E. G. (2006) · Forum of nutrition/Bibliotheca Nutritio et dieta · doi:10.1159/000095209 · Cited by 41
Mechanisms of Neurodegenerative Disorders
Wolozin, B. L., & Behl, C. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.801 · Cited by 41
Yoneda, F. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00002-5 · Cited by 41
Treatment of Alzheimer’s Disease: Current Approaches and Promising Developments
Small, G. W. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00027-8 · Cited by 41
Marin, D. B., Dugue, M., Schmeidler, J., Santoro, J., Neugroschl, J. A., Zaklad, G. R., Brickman, A. M., Schnur, E., Hoblyn, J. C., & Davis, K. L. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200008)15:8 · Cited by 41
Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
Saver, J. L., & Kalafut, M. A. (2001) · Neuroepidemiology · doi:10.1159/000054762 · Cited by 41
Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease
Adalier, N., & Parker, H. (2016) · Antioxidants · doi:10.3390/antiox5040040 · Cited by 40
Kleman, P., González‐Liste, P. J., García-Garrido, S. E., Cadierno, V., & Pizzano, A. (2014) · ACS Catalysis · doi:10.1021/cs501402z · Cited by 40
Traumatic Brain Injury and Suicidal Behavior: A Review
Wadhawan, A., Stiller, J. W., Potocki, E., Okusaga, O. O., Dagdag, A., Lowry, C. A., Benros, M. E., & Postolache, T. T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181055 · Cited by 40
Liu, G., Liu, X., Cai, Z., Jiao, G., Xu, G., & Tang, W. (2013) · Angewandte Chemie · doi:10.1002/ange.201300646 · Cited by 40
Anti-aging Effects of Cyanidin under a Stress-Induced Premature Senescence Cellular System
Choi, M. J., Kim, B. K., Park, K. Y., Yokozawa, T., Song, Y.-O., & Cho, E. J. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.421 · Cited by 40
The Effect of the Living Situation on the Severity of Dementia at Diagnosis
Sibley, A. K., MacKnight, C., Rockwood, K. J., Fisk, J. D., Gauthier, S. G., Guzman, D., & Hogan, D. B. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000048632 · Cited by 40
Carlsson, C. M., Papcke-Benson, K., Carnes, M. L., McBride, P. E., & Stein, J. H. (2002) · Drugs & Aging · doi:10.2165/00002512-200219100-00008 · Cited by 40
Qualitative versus quantitative caloric intake: are they equivalent paths to successful aging?
Casadesús, G., Shukitt‐Hale, B., & JOSEPH, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00079-9 · Cited by 40
Dynamics of Vitamin E Action against LDL Oxidation
Noguchi, N., & Niki, E. (1998) · Free Radical Research · doi:10.3109/10715769809065812 · Cited by 40
Estrogen and the Treatment of Alzheimer’s Disease
Birge, S. J., & Mortel, K. F. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00258-1 · Cited by 40
Dietary Lipids in the Aetiology of Alzheimer???s Disease
Cooper, J. L. (2003) · Drugs & Aging · doi:10.2165/00002512-200320060-00001 · Cited by 40
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
Dietary antioxidant intake and cognitive performance in middle-aged adults
Peacock, J. M., Folsom, A. R., Knopman, D. S., Mosley, T. H., Goff, D. C., & Szklo, M. (2000) · Public Health Nutrition · doi:10.1017/s1368980000000380 · Cited by 33
Progress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
The geriatric population and psychiatric medication
Varma, S., Sareen, H., & Trivedi, J. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58818 · Cited by 27
Di Stefano, A., Sozio, P., Cerasa, L. S., Iannitelli, A., Cataldi, A., Zara, S., Giorgioni, G., & Nasuti, C. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300221 · Cited by 26
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Faulks (2000) · doi:10.1002/(sici)1097-0010(20000515)80:7
- Self-citation
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
